BICO Acquires Assets and Operations of HUREL Corp. for ~$2.5M

UNILUX (AURELIUS portfolio) Acquires HBI Holz-Bau-Industrie

May 3, 2023

Building Products

UNILUX, a portfolio company of AURELIUS Equity Opportunities, has completed an add-on acquisition of HBI Holz-Bau-Industrie GmbH & Co. KG. The deal strengthens UNILUX's manufacturing footprint and product offering in high-quality windows and doors, enhancing its position in the DACH region.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Biocodex Acquires Majority Stake in Hilma

November 17, 2022

Pharmaceuticals

French pharmaceutical group Biocodex has acquired a majority stake in Hilma, a U.S.-based natural remedies start-up founded by Hilary Quartner, Nina Mullen and Lily Galef. The deal gives Biocodex a stronger foothold in the U.S. digestive-health and women’s-health segments and will help scale Hilma’s omnichannel retail strategy (DTC plus 750+ stores including Target).

ORIX Corporation USA Acquires Majority Stake in Hilco Global

September 2, 2025

Financial Services

ORIX Corporation USA has completed the acquisition of a majority equity stake in Hilco Global, which will operate as a subsidiary of ORIX USA while Hilco's executive leadership retains a minority ownership position. The transaction reorganizes Hilco into two divisions—Professional Services and Capital Solutions—to expand its valuation, advisory, and asset-based private credit capabilities leveraging ORIX USA's capital and lending expertise.

Labcorp Acquires Certain BioReference Health Laboratory Assets for $237.5M

March 28, 2024

Healthcare Services

Labcorp will acquire certain laboratory testing businesses and operating assets from Opko Health subsidiary BioReference Health for $237.5 million. The assets — which generate roughly $100 million in annual revenue — include patient service centers and select customer contracts across the U.S. (excluding New York and New Jersey); BioReference Health will retain its oncology and urology diagnostic businesses and full operations in New York and New Jersey. The transaction is expected to close in the second half of 2024, subject to customary conditions and regulatory approvals.